Prostate cancer pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:
==Pathogenesis==
==Pathogenesis==


**Prostate cancers can be lethal because they heterogeneously contain both androgen-dependent and androgen-independent malignant cells<ref name="pmid8602401">{{cite journal |vauthors=Denmeade SR, Lin XS, Isaacs JT |title=Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer |journal=Prostate |volume=28 |issue=4 |pages=251–65 |date=April 1996 |pmid=8602401 |doi=10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G |url=}}</ref>  
*Prostate cancers can be lethal because they heterogeneously contain both androgen-dependent and androgen-independent malignant cells<ref name="pmid8602401">{{cite journal |vauthors=Denmeade SR, Lin XS, Isaacs JT |title=Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer |journal=Prostate |volume=28 |issue=4 |pages=251–65 |date=April 1996 |pmid=8602401 |doi=10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G |url=}}</ref>  
*For those cells that are androgen dependent, a critical level of androgen is required to activate a sufficient number of androgen receptors (ARs) so that transcription of death-signaling genes is expressed  
*For those cells that are androgen dependent, a critical level of androgen is required to activate a sufficient number of androgen receptors (ARs) so that transcription of death-signaling genes is expressed  
*Androgens are capable of both stimulating proliferation as well as inhibiting the rate of the glandular epithelial cell death  
*Androgens are capable of both stimulating proliferation as well as inhibiting the rate of the glandular epithelial cell death  

Revision as of 17:14, 21 December 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Syed Musadiq Ali M.B.B.S.[2]

Prostate cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Prostate Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Staging

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Alternative Therapy

Case Studies

Case #1

Prostate cancer pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Prostate cancer pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Prostate cancer pathophysiology

CDC on Prostate cancer pathophysiology

Prostate cancer pathophysiology in the news

Blogs on Prostate cancer pathophysiology

Directions to Hospitals Treating Prostate cancer

Risk calculators and risk factors for Prostate cancer pathophysiology

Overview

On microscopic histopathological analysis, increased gland density, small circular glands, basal cells lacking, and cytological abnormalities are characteristic findings of prostate cancer.

Pathogenesis

  • Prostate cancers can be lethal because they heterogeneously contain both androgen-dependent and androgen-independent malignant cells[1]
  • For those cells that are androgen dependent, a critical level of androgen is required to activate a sufficient number of androgen receptors (ARs) so that transcription of death-signaling genes is expressed
  • Androgens are capable of both stimulating proliferation as well as inhibiting the rate of the glandular epithelial cell death
  • Androgen withdrawal triggers the programmed cell death pathway in both normal prostate glandular epithelia and androgen-dependent prostate cancer cells
  • Androgen withdrawal triggers the programmed cell death pathway in both normal prostate glandular epithelia and androgen-dependent prostate cancer cells
  • Androgen-independent prostate cancer cells do not initiate the programmed cell death pathway upon androgen ablation; however, they do retain the cellular machinery necessary to activate the programmed cell death cascade when sufficiently damaged by exogenous agents
  • Prostate cancer is classified as an adenocarcinoma, or glandular cancer. The region of prostate gland where the adenocarcinoma is most common is the peripheral zone.[2]
  • Although there is no proof that PIN is a cancer precursor, it is closely associated with cancer. Over time these cancer cells begin to multiply and spread to the surrounding prostate tissue (the stroma) forming a tumor.[3]
When normal cells are damaged beyond repair, they are eliminated by apoptosis. Cancer cells avoid apoptosis and continue to multiply in an unregulated manner.


  • Prostate gland is a zinc-accumulating, citrate-producing organ[4]
  • The protein ZIP1 is required for the active transport of zinc into prostate cells
  • Zinc have important role to change the metabolism of the cell in order to produce citrate, an important component of semen
  • The process of zinc accumulation and citrate production is energy inefficient and prostate cells sacrifice enormous of energy (ATP) in order to complete this task.
  • Prostate cancer cells are generally devoid of zinc. This allows prostate cancer cells to save energy not making citrate, and utilize the new abundance of energy to grow and spread
  • The absence of zinc is thought to occur via a silencing of the gene that producing the transporter protein ZIP1
  • ZIP1 is now called a tumor suppressor gene product for the gene SLC39A1.The cause of epigenetic silencing is unknown
  • Zinc inhibits BF-kB pathways, Is anti- proliferative,and induces apoptosis in abnormal cells
  • Unfortunately, oral ingestion of zinc is not effective because high concentrations of zinc into prostate cells is not possible without the active transporter ZIP1
  • RUNX2 is a transcription factor that prevents the cancer cells from undergoing apoptosis thereby contributing to the development of prostate cancer
  • The androgen receptor helps prostate cancer cells to survive and is a target for many anticancer research studies; so far, inhibiting androgen receptor
  • Prostate specific membrane antigen(PSMA) stimulates the development of prostate cancer by increasing folate levels for cancer cells to use to survive and grow
  • PSMA increases available folates for use by hydrolyzing glutamate folate

Gross Pathology

Prostate cancer is uncommonly apparent on gross.[5]

Microscopic Pathology

Major criteria:[6][7]

  • Architecture
  • Increased gland density
  • Small circular glands
  • In rare subtypes - large branching glands
  • Basal cells lacking
  • Cytological abnormalities:

Minor criteria:

Prostate adenocarcinoma: Microscopic View

{{#ev:youtube|1SZPLS1dxTo}}

Gleason score

Prostate: Adenocarcinoma (Gleason grade 1)

{{#ev:youtube|F7V0Zl7a2FY}}

Prostate: Adenocarcinoma (Gleason grade 2)

{{#ev:youtube|YSOLiSklIXw}}

Prostate: Adenocarcinoma (Gleason grade 3)

{{#ev:youtube|TG8vR_pE7yA}}

Prostate: Adenocarcinoma (Gleason grade 4)

{{#ev:youtube|R2Cl4HScdGc}}

Prostate: Adenocarcinoma (Gleason grade 5)

{{#ev:youtube|F7V0Zl7a2FY}}

References

  1. Denmeade SR, Lin XS, Isaacs JT (April 1996). "Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer". Prostate. 28 (4): 251–65. doi:10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G. PMID 8602401.
  2. "Prostate Cancer". National Cancer Institute. Retrieved 12 October 2014.
  3. 3.0 3.1 3.2 3.3 "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the original on 2011-04-28. Retrieved 2011-04-28. There are many connections between the prostatic venous plexus and the vertebral veins. The veins forming the prostatic plexus do not contain valves and it is thought that straining to urinate causes prostatic venous blood to flow in a reverse direction and enter the vertebral veins carrying malignant cells to the vertebral column.
  4. . doi:10.9790/0853-1506020411. Missing or empty |title= (help)
  5. Prostatic carcinoma.Dr Ian Bickle and Dr Saqba Farooq et al. Radiopaedia.org 2015.http://radiopaedia.org/articles/prostatic-carcinoma-1
  6. Humphrey PA (2007). "Diagnosis of adenocarcinoma in prostate needle biopsy tissue". J. Clin. Pathol. 60 (1): 35–42. doi:10.1136/jcp.2005.036442. PMC 1860598. PMID 17213347. Unknown parameter |month= ignored (help)
  7. "Prostate cancer.Libre pathology 2015".

Template:WH Template:WS